Literature DB >> 24413830

Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?

Ferdinando C M Cananzi1, Bruno Lorenzi, Ajay Belgaumkar, Charlotte Benson, Ian Judson, Satvinder Mudan.   

Abstract

PURPOSE: Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumour of the gastrointestinal tract. The introduction of tyrosine kinase inhibitors (TKIs) has lead to increasing use of combination of medical and surgical therapy. The aim of this study was to look at outcomes from a series of surgically treated GISTs and determine prognostic factors in the context of multimodal therapy.
METHODS: We analysed 104 single surgeon's patients with GIST. End points of the study were disease-specific survival (DSS), disease-free survival (DFS) and post-operative complications.
RESULTS: Three- and 5-year DSS rates were 96.7 and 94.6 %. On univariate analysis, clear resection margins were predictive of DSS. Patients with R2 resection had a worse prognosis (3-year DSS rate of 83.3 %; 5-year DSS rate of 62.5 %) compared to patients with R0 (3-year DSS rate of 98 %; 5-year DSS rate of 98 %) or R1 resection (3-year DSS rate of 100 %; 5-year DSS rate of 100 %) (R0 vs R1 vs. R2 p = 0.001). Pre-operative factors associated with R2 resection were clinical metastatic disease (p < 0.001), non-gastric tumour site (p = 0.002) and large tumour diameter (p = 0.031). Three- and 5-year DFS rates were 65.5 and 59.8 %. Serosal perforation (p = 0.013) and mitotic rate (p = 0.05) were found to be independently predictive of increased DFS. The presence of serosal perforation was associated with tumour site (p = 0.018), mitotic rate (p = 0.035), tumour diameter (p < 0.001), growth pattern (p = 0.007) and age (p = 0.040).
CONCLUSIONS: In the multidisciplinary management of GIST, serosal perforation may represent an additional predictor of recurrence along with mitotic rate. Complete macroscopic surgical resection is the most reliable prognostic factor, and an aggressive surgical approach should be advocated.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24413830     DOI: 10.1007/s00423-014-1160-3

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  59 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

3.  Surgical margin status and prognosis of gastrointestinal stromal tumor.

Authors:  António M Gouveia; Amadeu P Pimenta; Ana F Capelinha; Dionísio de la Cruz; Paula Silva; José M Lopes
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

4.  The effect of surgery and grade on outcome of gastrointestinal stromal tumors.

Authors:  J P Pierie; U Choudry; A Muzikansky; B Y Yeap; W W Souba; M J Ott
Journal:  Arch Surg       Date:  2001-04

5.  Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.

Authors:  Cristina R Antonescu; Peter Besmer; Tianhua Guo; Knarik Arkun; Glory Hom; Beata Koryotowski; Margaret A Leversha; Philip D Jeffrey; Diann Desantis; Samuel Singer; Murray F Brennan; Robert G Maki; Ronald P DeMatteo
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

Review 6.  Targeted therapies in soft tissue sarcomas.

Authors:  I Judson
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

7.  Heterogeneity of kinase inhibitor resistance mechanisms in GIST.

Authors:  B Liegl; I Kepten; C Le; M Zhu; G D Demetri; M C Heinrich; C D M Fletcher; C L Corless; J A Fletcher
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

8.  Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy.

Authors:  Mehrdad Nikfarjam; Eric Kimchi; Serene Shereef; Niraj J Gusani; Yixing Jiang; John Liang; Mandeep Sehmbey; Kevin F Staveley-O'Carroll
Journal:  J Gastrointest Surg       Date:  2008-06-11       Impact factor: 3.452

Review 9.  Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.

Authors:  Eva Wardelmann; Reinhard Büttner; Sabine Merkelbach-Bruse; Hans-Ulrich Schildhaus
Journal:  Virchows Arch       Date:  2007-08-14       Impact factor: 4.064

10.  Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.

Authors:  Piotr Rutkowski; Alessandro Gronchi; Peter Hohenberger; Sylvie Bonvalot; Patrick Schöffski; Sebastian Bauer; Elena Fumagalli; Pawel Nyckowski; Buu-Phuc Nguyen; Jan Martijn Kerst; Marco Fiore; Elzbieta Bylina; Mathias Hoiczyk; Annemieke Cats; Paolo G Casali; Axel Le Cesne; Jürgen Treckmann; Eberhard Stoeckle; Johannes H W de Wilt; Stefan Sleijfer; Ronald Tielen; Winette van der Graaf; Cornelis Verhoef; Frits van Coevorden
Journal:  Ann Surg Oncol       Date:  2013-06-13       Impact factor: 5.344

View more
  4 in total

1.  Microscopic positive tumor margin does not increase the rate of recurrence in endoscopic resected gastric mesenchymal tumors compared to negative tumor margin.

Authors:  Yan Zhu; Mei-Dong Xu; Chen Xu; Xiao-Cen Zhang; Shi-Yao Chen; Yun-Shi Zhong; Yi-Qun Zhang; Wei-Feng Chen; Tian-Yin Chen; Jia-Xin Xu; Li-Qing Yao; Quan-Lin Li; Ping-Hong Zhou
Journal:  Surg Endosc       Date:  2019-05-28       Impact factor: 4.584

2.  Predictive features of CT for risk stratifications in patients with primary gastrointestinal stromal tumour.

Authors:  Cuiping Zhou; Xiaohui Duan; Xiang Zhang; Huijun Hu; Dongye Wang; Jun Shen
Journal:  Eur Radiol       Date:  2015-12-23       Impact factor: 5.315

Review 3.  Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta-analysis.

Authors:  Xiaofei Zhi; Baofei Jiang; Junbo Yu; Oluf Dimitri Røe; Jun Qin; Qingfeng Ni; Luning Sun; Meirong Xu; Jianwei Zhu; Lilin Ma
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

Review 4.  Gastrointestinal stromal tumors: A multidisciplinary challenge.

Authors:  Juan Manuel Sanchez-Hidalgo; Manuel Duran-Martinez; Rafael Molero-Payan; Sebastian Rufian-Peña; Alvaro Arjona-Sanchez; Angela Casado-Adam; Antonio Cosano-Alvarez; Javier Briceño-Delgado
Journal:  World J Gastroenterol       Date:  2018-05-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.